Telomir Pharmaceuticals, Inc.
TELO
$4.53
-$0.505-10.04%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 322.64% | 448.69% | 336.63% | 5,628.50% | 11,121.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.08% | 212.65% | 106.23% | 322.05% | 359.71% |
| Operating Income | -212.08% | -212.65% | -106.23% | -322.05% | -359.71% |
| Income Before Tax | -26.94% | -444.02% | -580.57% | -1,379.55% | -1,424.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.94% | -444.02% | -580.57% | -1,379.55% | -1,424.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.94% | -444.02% | -580.57% | -1,379.55% | -1,424.41% |
| EBIT | -212.08% | -212.65% | -106.23% | -322.05% | -359.71% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -18.96% | -424.01% | -629.66% | -1,805.52% | -2,551.65% |
| Normalized Basic EPS | -178.51% | -247.96% | -334.48% | -1,048.89% | -1,040.71% |
| EPS Diluted | -18.96% | -424.01% | -629.66% | -1,805.52% | -2,551.65% |
| Normalized Diluted EPS | -178.51% | -247.96% | -334.48% | -1,048.89% | -1,040.71% |
| Average Basic Shares Outstanding | 7.82% | 5.72% | 38.05% | 103.01% | 303.23% |
| Average Diluted Shares Outstanding | 7.82% | 5.72% | 38.05% | 103.01% | 303.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
